Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finland moves forward with e-patient journal:

This article was originally published in Clinica

Executive Summary

Finland's aim to introduce a national electronic patient journal by the end of 2007 last week took a step forward when the working group, appointed by the ministry of social affairs and health to oversee its introduction, handed in its strategy report to health and social services minister Liisa Hyssala. The report contains details of the journal's structure, data transmission standards, and principles for data protection as required by the health service. Once the system has been fully introduced, doctors will be able to access patient treatment records from different healthcare institutions, provided they have gained the patient's prior consent. The health ministry also hopes that the journal will promote integrated care and improve the speed and efficiency of treatment.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT057168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel